Literature DB >> 21536148

Hepatocyte growth factor-induced c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway inhibits dendritic cell activation by blocking IκB kinase activity.

Eshu Singhal1, Pradip Sen.   

Abstract

Hepatocyte growth factor modulates activation and antigen-presenting cell function of dendritic cells. However, the molecular basis for immunoregulation of dendritic cells by hepatocyte growth factor is undefined. In the current study, we demonstrate that hepatocyte growth factor exhibits inhibitory effect on dendritic cell activation by blocking IκB kinase activity and subsequent nuclear factor-κB activation. Inhibition of IκB kinase is mediated by hepatocyte growth factor-induced activation of c-Src. Proximal signaling events induced in dendritic cells by hepatocyte growth factor include a physical association of c-Src with the hepatocyte growth factor receptor c-MET and concomitant activation of c-Src. Activation of c-Src in turn establishes a complex consisting of phosphatidylinositol 3-kinase and c-MET, and promotes downstream activation of the phosphatidylinositol 3-kinase/AKT pathway and mammalian target of rapamycin. Blocking activation of c-Src, phosphatidylinositol 3-kinase and mammalian target of rapamycin prevents hepatocyte growth factor-induced inhibition of IκB kinase, nuclear factor-κB and dendritic cell activation. Notably, hepatocyte growth factor-stimulated c-Src activation results in induction of phosphatidylinositol 3-kinase complexes p85α/p110α and p85α/p110δ, which is required for activation of mammalian target of rapamycin, and consequent inhibition of IκB kinase and nuclear factor-κB activation. Our findings, for the first time, have identified the c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway that plays a pivotal role in mediating the inhibitory effects of hepatocyte growth factor on dendritic cell activation by blocking nuclear factor-κB signaling.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536148     DOI: 10.1016/j.biocel.2011.04.006

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  13 in total

Review 1.  Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Authors:  Neil Gildener-Leapman; Robert L Ferris; Julie E Bauman
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

2.  Activated apoptotic cells induce dendritic cell maturation via engagement of Toll-like receptor 4 (TLR4), dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN), and β2 integrins.

Authors:  Sushil Kumar Pathak; Annette E Sköld; Venkatramanan Mohanram; Catrine Persson; Ulrika Johansson; Anna-Lena Spetz
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

3.  Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.

Authors:  Shumei Kato; Denis L Jardim; Faye M Johnson; Vivek Subbiah; Sarina Piha-Paul; Apostolia M Tsimberidou; Gerald S Falchook; Daniel Karp; Ralph Zinner; Jennifer Wheler; Filip Janku; Siqing Fu; JoAnn Lim; Stacie Bean; Ly Nguyen; Susan Urban; Elsa Browne; Funda Meric-Bernstam; David S Hong
Journal:  Invest New Drugs       Date:  2017-10-19       Impact factor: 3.850

4.  A novel role for Bruton's tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells.

Authors:  Eshu Singhal; Prakash Kumar; Pradip Sen
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

5.  Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.

Authors:  L Zhou; X-D Liu; M Sun; X Zhang; P German; S Bai; Z Ding; N Tannir; C G Wood; S F Matin; J A Karam; P Tamboli; K Sircar; P Rao; E B Rankin; D A Laird; A G Hoang; C L Walker; A J Giaccia; E Jonasch
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

Review 6.  Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.

Authors:  Julie E Bauman; Robert L Ferris
Journal:  Cancer       Date:  2013-11-12       Impact factor: 6.860

7.  Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.

Authors:  Anna R Kwilas; Andressa Ardiani; Renee N Donahue; Dana T Aftab; James W Hodge
Journal:  J Transl Med       Date:  2014-11-13       Impact factor: 5.531

Review 8.  HGF/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells.

Authors:  Jessica Hübel; Thomas Hieronymus
Journal:  Biomedicines       Date:  2015-03-03

Review 9.  Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.

Authors:  Xing Huang; Enliang Li; Hang Shen; Xun Wang; Tianyu Tang; Xiaozhen Zhang; Jian Xu; Zengwei Tang; Chengxiang Guo; Xueli Bai; Tingbo Liang
Journal:  Front Cell Dev Biol       Date:  2020-05-06

Review 10.  The Impact of the Epithelial-Mesenchymal Transition Regulator Hepatocyte Growth Factor Receptor/Met on Skin Immunity by Modulating Langerhans Cell Migration.

Authors:  Zsofia Sagi; Thomas Hieronymus
Journal:  Front Immunol       Date:  2018-03-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.